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Abstract
Importance: Small cell carcinoma/neuroendocrine prostate cancer (NePC) is a lethal, poorly understood prostate
cancer (PCa) subtype. Controversy exists about the origin of NePC in this setting.
Objective: To molecularly profile archived biopsy specimens from a case of early-onset PCa that rapidly progressed
to NePC to identify drivers of the aggressive course and mechanisms of NePC origin and progression.
Design, setting, and participants: A 47-year-old patient presented with metastatic prostatic adenocarcinoma
(Gleason score 9). After a 6-month response to androgen deprivation therapy, the patient developed jaundice and
liver biopsy revealed exclusively NePC. Targeted next generation sequencing (NGS) from formalin-fixed
paraffin-embedded (FFPE)-isolated DNA was performed from the diagnostic prostate biopsy and the liver
biopsy at progression.
Intervention: Androgen deprivation therapy for adenocarcinoma followed by multiagent chemotherapy for NePC.
Main outcomes and measures: Identification of the mutational landscape in primary adenocarcinoma and NePC liver
metastasis. Whether the NePC arose independently or was derived from the primary adenocarcinoma was considered
based on mutational profiles.
Results: A deleterious somatic SMAD4 L535fs variant was present in both prostate and liver specimens; however, a
TP53 R282W mutation was exclusively enriched in the liver specimen. Copy number analysis identified concordant,
low-level alterations in both specimens, with focal MYCL amplification and homozygous PTEN, RB1, and MAP2K4 losses
identified exclusively in the NePC specimen. Integration with published genomic profiles identified MYCL as a
recurrently amplified in NePC.
Conclusions and relevance: NGS of routine biopsy samples from an exceptional non-responder identified SMAD4 as a
driver of the aggressive course and supports derivation of NePC from primary adenocarcinoma (transdifferentiation).
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Introduction
Precision oncology heralds an era in which tumors are
biopsied and profiled in the metastatic setting with the
goal of identifying therapeutic targets. Although next
generation sequencing (NGS) of “N of 1” cases have
identified mechanisms of exceptional response to inves-
tigational therapies [1–4], such approaches have largely
not been applied to exceptional non-responders. Like-
wise, NGS profiling of pre-/post-treatment samples in
cases with marked histologic progression, which enables
assessment of progression mechanisms, is challenging
due to difficulties in obtaining and assessing routine
diagnostic biopsy samples. Here, we describe NGS as-
sessment of routine clinical samples from a patient diag-
nosed with metastatic PCa at a young age who rapidly
progressed and died from disease approximately 1 year
from diagnosis. Importantly, while his primary tumor ex-
clusively contained conventional prostatic adenocarcin-
oma, a post-treatment liver metastasis biopsy exclusively
contained prostatic small cell carcinoma/NePC. Hence,
this case provided a unique opportunity to assess the
utility of NGS-based profiling of serial routine biopsy
specimens from an “exceptional non-responder” who
showed rapid histologic progression during treatment.
Methods
Study oversight
The patient signed a consent form to participate in an
IRB-approved research study to sequence tumor and
germline DNA from men presenting with metastatic
PCa before age 60 years.
Tumor sequencing and analysis
Post-mortem, we performed targeted next generation se-
quencing (NGS) on DNA and RNA co-isolated from
macrodissected formalin-fixed paraffin-embedded (FFPE)
tissue sections from the original diagnostic prostate biopsy
specimen (PR-259) and the post-treatment liver biopsy
specimen (PR-258). Multiplexed PCR-based NGS (Ampli-
seq) was performed using 40-ng DNA and the Ion Tor-
rent Comprehensive Cancer Panel (CCP), which targets
the coding region of 409 cancer-related genes with 15,992
amplicons (1,688,650 targeted bases) [5, 6]. Multiplexed
PCR-based NGS (Ampliseq) was also performed using
20 ng RNA and the RNA component of the Oncomine
Comprhensive Panel (OCP), which uses a total of 154 pri-
mer pairs to target known gene fusion isoforms, including
those involving recurrent 5’ (TMPRSS2, SLC45A3,
C15ORF21) and 3’ (ERG, ETV1, ETV4, ETV5, and BRAF)
fusion partners in PCa [7]. Detailed description of sequen-
cing, data analysis using validated pipelines, sequencing
statistics, and all identified high-confidence somatic vari-
ants are given in the Supplement (Additional file 1 and
Tables 1 and 2).
Case presentation
A 47-year-old male participated in PCa screening due to
positive family history of PCa (father). Prostate-specific
antigen (PSA) was initially elevated at 13.3 ng/mL, how-
ever, prostate biopsy was negative. His PSA rose one
year later to 170 ng/mL, and repeat prostate biopsy re-
vealed Gleason 4 + 5 = 9 prostate adenocarcinoma in-
volving all 12 cores (Fig. 1, top and middle panels).
Computed tomography (CT) of the abdomen and pelvis
showed an enlarged left iliac lymph node but no other me-
tastases. Bone-scan showed metastases involving the lum-
bar vertebrae. He enrolled in a clinical trial and was
treated with an oral anti-androgen along with leuprolide.
On this regimen, PSA decreased to a nadir of <4.0 ng/mL
over 6 months, and CT scan showed reduction in the size
of the enlarged iliac node and normal liver parenchyma.
Two months later, the patient presented with jaundice
and was found to have elevated transaminases. MRI
showed a pseudocirrhotic appearance of the liver (Fig. 2).
Liver biopsy revealed small cell/NePC (Fig. 1, bottom
panel). Despite poor performance status and after dis-
cussion of risks and benefits, he was initiated on dose-
reduced oral etoposide along with carboplatin and
Table 1 Sequencing statistics for the diagnostic prostate biopsy
sample containing conventional adenocarcinoma (PR-259) and




Mapped reads (n) 25,670,652 2,937,737
On target reads (%) 98.1 % 99.0 %
Total aligned base reads 2,672,758,224 322,308,287
Total base reads on target 2,562,288,371 310,618,776
Average base coverage depth 1,517 184
Uniformity of base coverage 51.2 % 90.9 %
Target base coverage at 20× 89.9 % 94.2 %
Target base coverage at 100× 71.7 % 72.4 %
Target bases with no strand bias 93.5 % 93.3 %
Total called variantsa 2,556 1,177
Variants passing filteringb 5 6
Somatic variantsc 3 4
Prioritized somatic variantsd 1 2
RNA sequencing
Total reads (n) 66,564 247,655
Uniquely mapped to genome (%) 38 % 79 %
Identified gene fusions (n) 0 0
aVariants called by automated low stringency variant calling
bVariants passing filtering of technical artifacts, poorly supported variants,
germline SNPs and synonymous/non-coding variants
cVariants confirmed as somatic through exome sequencing of germline DNA
dSomatic variants prioritized as likely driving oncogenic or tumor suppressive
mutations as described in the eMethods
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continued leuprolide. Although the patient demon-
strated an initial clinical response, he elected to end
treatment. He died under hospice care 3 months follow-
ing NePC diagnosis.
Results
NGS of DNA isolated from the routine FFPE diagnostic
prostate biopsy specimen (PR-259) and the post-
treatment liver biopsy specimen (PR-258) identified a
total of two prioritized high-confidence somatic variants.
As shown in Fig. 3, a SMAD4 c1605delC p.L535fs frame-
shifting variant was present in both PR-259 (36 % variant
allele frequency) and PR-258 (67 % variant allele fre-
quency). In contrast, a TP53 c.C844T p.R282W non-
synonymous variant was exclusively called in the NePC
specimen (PR-258; 69 % variant allele frequency). This
variant was markedly enriched in PR-258, and was only
present at a variant allele frequency of 1.6 % (12/755
reads) in the diagnostic pre-treatment specimen (PR-
259). These results are consistent with clonal origin and
marked enrichment of the TP53 R282W variant exclu-
sively in the post-treatment NePC specimen. Exome se-
quencing of germ line DNA isolated from white blood
cells confirmed the TP53 and SMAD4 variants as som-
atic (see Table 2).
We next compared NGS-derived copy number profiles
between PR-259 and PR-258 using our well-validated ap-
proach [5–7]. Copy number profiling revealed broad one
copy loss of 10q (containing PTEN), 18q, and a complex
alteration on chromosome 19 in both specimens, whereas
the post-treatment liver biopsy (PR-258) exclusively dem-
onstrated focal, high-level MYCL amplification, and focal
homozygous PTEN, RB1, and MAP2K4 deletions. Lastly,
no gene fusions were identified in either PR-259 or PR-
258 from targeted multiplexed PCR-based RNAseq on co-
isolated RNA (see Additional file 1). Taken together with
the somatic variant analysis, copy number profiling
supported the clonal relationship between PR-259 and
PR-285, and identified highly enriched, focal, high-
level copy number alterations in the post-therapy
NePC specimen.
Discussion
Small cell carcinoma/(NePC) is a rare PCa variant with
an aggressive phenotype. Although de novo NePC con-
stitutes <1 % of all PCa, autopsy series of castration-
resistant prostate cancer (CRPCa) suggest the presence
of NePC in 10–25 % of cases [8]. Despite high initial
overall response rates (75–85 %) to platinum combina-
tions, relapse to a chemo-refractory state is nearly uni-
versal with a median survival of less than 18 months [9].
Although initially posited as due to clonal selection of
malignant neuroendocrine cells [10, 11], recent genetic
evidence supports a model of NePC development due to
transformation of prostate adenocarcinoma cells to a
neuroendocrine phenotype, termed transdifferentiation
(see review [12]). Consistent with the concept of a com-
mon clonal origin, recurrent prostate adenocarcinoma-
specific alterations, such as recurrent ETS gene rear-
rangements, show concordant status in PCa admixed
with NePC, and ETS rearrangement frequency is similar
in conventional PCa and NePC [13–15]. Additionally,
identical mutations in the DNA-binding domains of
TP53 have been observed in paired prostate adenocar-
cinoma and NePC [16]. The molecular mechanism of
NePC development via transdifferentiation is also sup-
ported by a recent report showing gene amplification of
AURKA and MYCN present in 65 % of adenocarcinomas
that develop into NePC following ADT whereas only
5 % of unselected adenocarcinomas showing similar am-
plifications [17]. Lastly, RNAseq profiling in matched
NePC and prostate adenocarcinomas showed downregu-
lation of the transcriptional complex REST, which is in-
tegral to the repression of neuronal differentiation [18].
Table 2 High confidence, non-synonymous variants identified in the diagnostic prostate biopsy sample containing conventional
adenocarcinoma (Dx [PR-259]) and subsequent liver metastasis with small cell/neuroendocrine carcinoma (NePC [PR-258])
Dx (PR-259) NePC (PR-258)









chr17:7577094 TP53 G A p.R282W 1.6 % 755 69 % 217 NM_000546 c.C844T
chr18:48604783 SMAD4 C – p.L535fs 36 % 227 67 % 196 NM_005359 c.1605delC
chr12:49449077 KMT2D T C p.K11E 18 % 22 37 % 180 NM_003482 c.A31G
chr5:7878077 MTRR C G p.P141R 15 % 89 55 % 142 NM_002454 c.C422G
chr19:17953318 JAK3 C T p.R223H 54 % 76 60 % 70 NM_000215 c.G668A
chr6:32166327 NOTCH4 T C p.T1543A 42 % 608 35 % 231 NM_004557 c.A4627G
High confidence, non-synonymous variants identified in the diagnostic prostate biopsy sample containing conventional adenocarcinoma (Dx [PR-259]) and paired
subsequent liver metastasis with small cell/neuroendocrine carcinoma (NePC [PR-258]) are shown. For each variant, the location (hg19), gene, reference (Ref.) and
variant (Alt.) alleles, and amino acid (AA) change info is given. The variant (Var.) allele frequency is the flow-corrected variant containing read count (FAO) divided
by flow-corrected read depth (FDP). For the KMT2D and TP53 variants in PR-259, the Var allele frequency was calculated using non-flow-corrected read counts
(AO/DP) due to those variants not passing filtering in that sample. The reference sequence (Refseq) and nucleotide (Nuc) change used to derive the AA change
are also given. Variants identified as SNPs by exome sequencing of germline DNA are indicated in gray. Prioritized somatic variants are bolded
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Despite the growing evidence in support of transdiffer-
entiation, limited data has been published comparing
comprehensive molecular profiling of a primary prostate
adenocarcinoma and the subsequent metastatic NePC.
Our current study reflects, to our knowledge, the first
comprehensive profiling of paired diagnostic FFPE bi-
opsy and subsequent NePC specimens. The presence of
a somatic, deleterious SMAD4 variant in both the diag-
nostic and NePC specimens is consistent with clonal ori-
gin and the transdifferentiation model. Among 816
sequenced PCas in the cBioPortal database [19], six
(0.7 %) harbor somatic SMAD4 mutations, including one
sample with two SMAD4 mutations (Table 3). Import-
antly, six of the seven reported mutations impact the
MH2 domain (including known inactivating and truncat-
ing mutations [20,21]) and are recurrent in the COSMIC
database [22]. Of note, detailed mechanistic studies
demonstrate that SMAD4 loss leads to an aggressive
PCa phenotype in mouse models [23], providing a likely
candidate driver of the aggressive phenotype in this ex-
ceptional “non-responder.”
The TP53 p.R282W mutation enrichment and homo-
zygous RB1 loss in the NePC sample herein supports
single gene studies and our recent targeted NGS profil-
ing of eight NePC that show frequent inactivation of
these genes in NePC [7, 24, 25]. Likewise, in a recent
study, we used qRT-PCR and a combination of exome/
targeted NGS to profile distinct conventional PCa and
NePC components from an FFPE transurethral resection
specimen, which demonstrated enrichment of a TP53
p.N151fs mutation exclusively in the NePC component
[26]. Although both oncogenic and metastasis suppressive
roles for MAP2K4 have been reported in PCa [27–29], its
role in NePC has not been described and will require add-
itional investigation.
As described above, recurrent MYCN amplifications
have been well-described in NePC [17]. Although a recent
report identified recurrent MYCL amplifications in ~25 %
of untreated Gleason score 7 PCa (>2 copies in 8–20 % of
malignant glands) [30], clonal, high-levelMYCL amplifica-
tions have not been observed in 1166 prior SNP-, aCGH-,
or NGS-based copy number profiled untreated PCa or
CRPC in cBioPortal (Table 3). However, in our previous
NGS-based profiling of 116 aggressive PCas, we identified
a single NePC (of 8 profiled) that harbored a high-level
MCYL amplification (Additional file 2: Figure S1) [7].
Likewise, copy number profiling of mouse NePC resulting
from prostate-specific p53 and RB inactivation identified
recurrent MYCL gains [31]. MYCL amplifications and
Fig. 2 MRI Liver at the time of clinical progression. Axial T2-weighted
MRI shows interval development of innumerable solid lesions in the
liver, replacing a majority of the parenchyma in both hepatic lobes
with development of a pseudocirrhotic appearance of the liver with a
nodular surface contour
Fig. 1 Histology of diagnostic (Dx) prostate biopsy (PR-259) with
Gleason score 4 + 5 = 9 adenocarcinoma and subsequent post-treatment
(Tx) liver biopsy (PR-258) containing small cell/neuroendocrine prostate
carcinoma (NePC). Hematoxylin and eosin-stained diagnostic biopsy
cores (top and middle panels) and liver biopsy (bottom panel) are shown.
Original magnification 10× (insets indicated by green boxes 40×)
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gene fusions have also been identified and shown to drive
proliferation in small cell lung carcinomas [32–34]. Taken
together with our previous NGS profiling study, herein we
identify recurrent MYCL1 amplifications in NePC, which
will need to be confirmed in additional NePC cohorts.
Alternate mechanisms for the development and main-
tenance of NE transdifferentiation have been described.
The process of “epithelial plasticity” provides evidence
for the diverse phenotype of NE-like tumor cells, such as
the variable expression of epithelial and NE markers
following androgen deprivation [12, 35–37]. This plasti-
city, which can occur via epithelial-to-mesenchymal
transition (EMT) or mesenchymal-to-epithelial transi-
tion (MET), is regulated by a complex system of tran-
scriptional networks and signaling pathways. The
TMPRSS2-ERG fusion gene and certain microRNAs (i.e.,
miR-200 family) appear to promote the EMT phenotype
leading, in part, to the castrate-resistant state [38, 39].
Importantly, neuroendocrine cancers involving other
organ sites appear to have distinct molecular aberrations
Fig. 3 Next generation sequencing (NGS) genomic profiles support transdifferentiaton from prostatic adenocarcinoma (PR-259) to small
cell/neuroendocrine prostate carcinoma (NePC, PR-258). Copy number plots and prioritized somatic mutations are shown. Points represent
the log2 copy number ratio for all targeted genes (shown in genome order). Clonal gains and losses are shown in red and blue, respectively. Prioritized
high-level copy number alterations (CNAs) alterations and somatic mutations (with variant allele frequency [%] and coverage depth [x]) are indicated.
Clonal prioritized SMAD4 mutation and SCC enriched TP53 mutation and MYCL, PTEN, RB1, and MAP2K4 copy number alterations are indicated
Table 3 SMAD4 mutation and MYCL1 amplification frequency in prostate cancer NGS and copy number profiling studies available in
cBioPortal








Prostate (Broad/Cornell 2013) PCa 57 56 1 (1.8 %) 0 (0 %)
Prostate (TCGA 2015) PCa 333 492 3 (0.9 %) 0 (0 %)
Prostate (Broad/Cornell 2012) PCa 112 109 1 (0.9 %) 0 (0 %)
Prostate (MSKCC 2014) PCa N/A 104 N/A 0 (0 %)
Prostate (MICH) PCa and CRPC 61 61 1 (1.6 %) 0 (0 %)
Prostate (MSKCC 2010) PCa and CRPC 103 194 0 (0 %) 0 (0 %)
Prostate (SU2C) CRPC 150 150 0 (0 %) 0 (0 %)
Hovelson et al. 2015 PCa and CRPC N/A* 116 N/A 1^ (0.8 %)
Total 816 1282 6 (0.7 %) 1 (0.08 %)
cBioPortal was queried for SMAD4 mutations and MYCL amplifications in prostate cancer tissue profiling studies. Sample types (localized untreated prostate
adenocarcinoma [PCa] and/or castration-resistant prostate cancer [CRPC], the number of cases with mutation or copy number alteration (CNA) data, and the number
(and %) of cases with SMAD4 mutations and MYCL amplifications are given
^,*Data from our recent targeted NGS study (Hovelson et al. 2015) which assessed MYCL but not SMAD4 is also included. The MYCL amplified case in that study
was small cell/neuroendocrine prostate cancer (NePC). Totals from cBioPortal and our previous study for each parameter is given
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and highlight the need for individualized therapies [40].
For example, telomerase reverse transcriptase (TERT)
promoter mutations are observed in many human epi-
thelial cancers as well as the vast majority of urothelial
neuroendocrine carcinomas, however, they are rarely
found in NE-prostate or -lung cancers [41, 42]. Given
the molecular heterogeneity of neuroendocrine carcinomas,
targeted approaches guided by appropriate biomarker iden-
tification, rather than or in addition to cytotoxic therapies,
are paramount to improve outcomes [43].
A variety of novel therapeutics targeting receptor tyro-
sine kinases, mammalian target of rapamycin (mTOR),
angiogenesis, cell cycle, epigenetics, and immunotherapy
have been tested, largely in small cell lung cancer, with
limited success [44, 45]. Specific to the mutational land-
scape of NEPC, a number of targeted therapies have
been investigated in in vitro and in murine models with
varied success (see review [46]). Targeting tumor suppres-
sor loss (TP53, RB1, and PTEN) is particularly relevant to
NEPC given the high frequency of these alterations. For
example, SAR405838, a novel small molecule inhibitor of
the oncoprotein murine double minute 2 (MDM2)-TP53
protein-protein interaction, showed significant activity in
wild-type TP53 murine models, including LNCaP prostate
cancer lines [47]. Multiple small molecules that can acti-
vate TP53 are in early phase clinical trials, however, none
at this time are recruiting patients with NEPC [46,48]. A
phase II study of MLN8237, a small molecule inhibitor of
Aurora Kinase A, is currently the only molecularly tar-
geted trial enrolling men with CRPC with neuroendocrine
features (NCT01799278).
A limitation of the current report is that it is based on
NGS from one patient. Future case studies should con-
sider application of immunohistochemical and morpho-
proteomic analyses, which might elucidate alternative
mechanisms of resistance. The application of these tools
has previously revealed means of response and resistance
in two cases of refractory Ewing sarcoma that responded
to combination therapy with insulin-like growth factor 1
receptor and mTOR inhibition [49].
“N of 1” cases provide unique hypothesis-generating
opportunities with the potential to provide new informa-
tion about pathogenic mechanisms and/or therapeutic
response [2, 4]. We suggest that profiling of “exceptional
non-responders” and temporally/histologically distinct
tumor components [26, 50], as shown herein, may be as
informative as “exceptional responder” studies and can
exploit the wealth of archived diagnostic tissue speci-
mens. Such studies may be particularly important for
identifying the prognostic and predictive associations of
rare alterations, such as SMAD4 mutations in prostate
cancer, as well as identifying adaptive alterations associ-
ated with treatment resistance/progression such as
MCYL amplifications.
Conclusions
Through comprehensive profiling of archived diagnostic
and liver biopsy specimens from a single patient with an
aggressive clinical course, we identify molecular alterations
associated with rapid progression from prostatic adenocar-
cinoma to NePC, and more broadly identifyMYCL as a re-
currently amplified gene specifically in NePC.
Additional files
Additional file 1: Molecular analysis of transdifferentiation from
prostate adenocarcinoma to small cell carcinoma/neuroendocrine
prostate cancer. (DOCX 55 kb)
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utilized to conduct the targeted next generation sequencing and
corresponding references. (AI 11975 kb)
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